Unannounced FDA Inspections Without Borders
Unannounced FDA inspections are no longer limited to the U.S. — they’re expanding globally. Starting in 2025, foreign sites will face the same surprise visits and public scrutiny as U.S. facilities, raising the stakes for sponsors and manufacturers alike.
A single failed inspection can derail years of investment, delay patient access, and damage investor confidence. Readiness can’t be a one-time effort; it must be embedded in daily operations. ProPharma’s experts provide end-to-end support, gap analyses, SME training, mock inspections, and ongoing audits, so your quality systems are inspection-ready every day, not just on paper.
Learn how to safeguard your operations and stay compliant in an era of real-time FDA evaluations and worldwide regulatory pressure.
Related Resources
The Cost of Poor Project Management
Project Management isn’t for the faint of heart. There is a shockingly high rate of project failure… but on the other hand, great project management can be a key differentiator that leads a company...
Successfully Passing MHRA Inspections for Overseas Manufacturing Sites
ProPharma offers GMP and GDP compliance services from clinical development to commercial distribution of the products' lifecycle. ProPharma’s Compliance and Quality team completed the first on-site...
Navigating the Generic Drug Application and Approval Process
Navigating the generic drug application and approval process can be challenging. From pre-filing through post-approval, find out exactly what needs to be done for your Abbreviated New Drug...